Briacell presents Bria-OTS+ preclinical results at SITC

Executive Summary

• Briacell Therapeutics is presenting preclinical data at the SITC 2025 Annual Meeting demonstrating robust anti-cancer activity and immune system engagement for its next-generation Bria-OTS+ platform.
• The data highlights rapid, potent, and durable anti-cancer responses in preclinical models for lead candidates Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer), driven by the activation of both innate and adaptive immune systems.
• The presentation reinforces the broad applicability of the Bria-OTS+ platform across multiple solid tumor indications, with Bria-PROS+ supported by a $2 million NCI SBIR award for upcoming Phase 1/2a clinical trials.

Key Details

• Event: Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting.
• Presentation Title: "Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance."
• Abstract Number: 353.
• Presentation Schedule: Friday, Nov. 7, 2025, from 12:15 to 1:45 p.m. and 5:35 to 7:00 p.m. ET.
• Platform: Bria-OTS+, an enhanced version of the Bria-OTS platform designed to express multiple immune-activating cytokines and co-stimulatory molecules.
• Lead Candidates:
  • Bria-BRES+: Targeting breast cancer.
  • Bria-PROS+: Targeting prostate cancer.
• Preclinical Findings:
  • Rapid activation of key immune system components.
  • Coordinated innate and adaptive immune responses.
  • Increased tumor cell cytotoxicity.
  • Sustained and durable anti-cancer immune responses suggesting prolonged clinical benefit.
• Manufacturing Status: Both Bria-BRES+ and Bria-PROS+ have completed Good Manufacturing Practice (GMP) manufacturing.
• Clinical Pipeline: Candidates are expected to be evaluated in upcoming Phase 1/2a clinical studies.
• Funding: Bria-PROS+ is supported by a $2-million National Cancer Institute (NCI) Small Business Innovative Research (SBIR) award, announced on Aug. 25, 2025.
• Historical Context: The parent platform, Bria-OTS, previously demonstrated positive clinical results as announced on April 24, 2025.

Notable Quotes

• Miguel A. Lopez-Lago, PhD, Chief Scientific Officer: "We are thrilled with the comprehensive, powerful and long-lasting immune activation demonstrated by Bria-OTS+ in our preclinical studies, which we believe will translate into meaningful anti-cancer immune responses in the clinic... By training both the innate and adaptive arms of the immune system, Bria-OTS+ represents an important step toward developing more durable and broadly effective cancer immunotherapies."
• Dr. William V. Williams, President and CEO: "These findings add to the growing body of evidence supporting our Bria-OTS+ platform's unique mechanism of action for novel personalized cancer immunotherapies. We look forward to confirming these encouraging preclinical results in planned clinical trials of Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer."